GlassScriptPhysician profile
Kirk Warren Brody
NPI 1497720759
$10,883.03
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $11K.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aegea Medical, INC. | $10,415.00 | 2019-2020 | |
| Roche Diagnostics Corporation | $92.57 | 2019-2020 | |
| Abbvie INC. | $62.91 | 2019-2020 | |
| Therapeuticsmd, INC. | $53.93 | 2019-2020 | |
| Lilly USA, LLC | $48.28 | 2019-2020 | |
| Axonics, INC. | $41.73 | 2020 | |
| Allergan, INC. | $38.95 | 2019 | |
| Hologic Sales and Service, LLC | $31.45 | 2019 | |
| Pfizer INC. | $29.84 | 2020 | |
| Daiichi Sankyo INC. | $28.06 | 2019 | |
| Lupin INC. | $15.20 | 2020 | |
| Exeltis, USA INC. | $13.91 | 2020 | |
| Minerva Surgical, INC | $11.20 | 2019 |
10 companies reported research payments only; those appear in the research section below.
Research and ownership
$5,688.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kirk Brody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.